BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30075439)

  • 1. Heparanase inhibition attenuates atherosclerosis progression and liver steatosis in E
    Muhammad RS; Abu-Saleh N; Kinaneh S; Agbaria M; Sabo E; Grajeda-Iglesias C; Volkova N; Hamoud S
    Atherosclerosis; 2018 Sep; 276():155-162. PubMed ID: 30075439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparanase Inhibition Reduces Glucose Levels, Blood Pressure, and Oxidative Stress in Apolipoprotein E Knockout Mice.
    Hamoud S; Shekh Muhammad R; Abu-Saleh N; Hassan A; Zohar Y; Hayek T
    Biomed Res Int; 2017; 2017():7357495. PubMed ID: 29226146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparanase Inhibition Prevents Liver Steatosis in E
    Kinaneh S; Hijaze W; Mansour-Wattad L; Hammoud R; Zaidani H; Kabala A; Hamoud S
    J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calpain inhibitor prevents atherosclerosis in apolipoprotein E knockout mice by regulating mRNA expression of genes related to cholesterol uptake and efflux.
    Liu J; Wang Q; Wei Y; Zhang S; Chai E; Tang F
    Microvasc Res; 2022 Mar; 140():104276. PubMed ID: 34742813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparanase promotes the onset and progression of atherosclerosis in apolipoprotein E gene knockout mice.
    Nguyen TK; Paone S; Baxter AA; Mayfosh AJ; Phan TK; Chan E; Peter K; Poon IKH; Thomas SR; Hulett MD
    Atherosclerosis; 2024 May; 392():117519. PubMed ID: 38581737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial aldehyde dehydrogenase activation by Alda-1 inhibits atherosclerosis and attenuates hepatic steatosis in apolipoprotein E-knockout mice.
    Stachowicz A; Olszanecki R; Suski M; Wiśniewska A; Totoń-Żurańska J; Madej J; Jawień J; Białas M; Okoń K; Gajda M; Głombik K; Basta-Kaim A; Korbut R
    J Am Heart Assoc; 2014 Nov; 3(6):e001329. PubMed ID: 25392542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. G004, a synthetic sulfonylurea compound, exerts anti-atherosclerosis effects by targeting SIRT1 in ApoE
    Qian L; Ma L; Wu G; Yu Q; Lin H; Ying Q; Wen D; Gao C
    Vascul Pharmacol; 2017 Feb; 89():49-57. PubMed ID: 28069546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis.
    Rahtu-Korpela L; Määttä J; Dimova EY; Hörkkö S; Gylling H; Walkinshaw G; Hakkola J; Kivirikko KI; Myllyharju J; Serpi R; Koivunen P
    Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):608-17. PubMed ID: 26848160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of PRMT3 activity reduces hepatic steatosis without altering atherosclerosis susceptibility in apoE knockout mice.
    Hoekstra M; Nahon JE; de Jong LM; Kröner MJ; de Leeuw LR; Van Eck M
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1402-1409. PubMed ID: 30776415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice.
    Nasiri-Ansari Ν; Dimitriadis GK; Agrogiannis G; Perrea D; Kostakis ID; Kaltsas G; Papavassiliou AG; Randeva HS; Kassi E
    Cardiovasc Diabetol; 2018 Jul; 17(1):106. PubMed ID: 30049285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of tocopheryl phosphates (TPM) on the development of atherosclerosis in apolipoprotein-E deficient mice.
    Libinaki R; Vinh A; Tesanovic-Klajic S; Widdop R; Gaspari T
    Clin Exp Pharmacol Physiol; 2017 Dec; 44 Suppl 1():107-116. PubMed ID: 28744946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydromyricetin ameliorates atherosclerosis in LDL receptor deficient mice.
    Liu TT; Zeng Y; Tang K; Chen X; Zhang W; Xu XL
    Atherosclerosis; 2017 Jul; 262():39-50. PubMed ID: 28500865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.
    Chen Y; Duan Y; Yang X; Sun L; Liu M; Wang Q; Ma X; Zhang W; Li X; Hu W; Miao RQ; Xiang R; Hajjar DP; Han J
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):948-59. PubMed ID: 25810299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exenatide mitigated diet-induced vascular aging and atherosclerotic plaque growth in ApoE-deficient mice under chronic stress.
    Yang G; Lei Y; Inoue A; Piao L; Hu L; Jiang H; Sasaki T; Wu H; Xu W; Yu C; Zhao G; Ogasawara S; Okumura K; Kuzuya M; Cheng XW
    Atherosclerosis; 2017 Sep; 264():1-10. PubMed ID: 28734203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Danhong Injection Attenuates High-Fat-Induced Atherosclerosis and Macrophage Lipid Accumulation by Regulating the PI3K/AKT Insulin Pathway.
    Zhou M; Ren P; Li S; Kang Q; Zhang Y; Liu W; Shang J; Gong Y; Liu H
    J Cardiovasc Pharmacol; 2019 Aug; 74(2):152-161. PubMed ID: 31306371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmalogen modulation attenuates atherosclerosis in ApoE- and ApoE/GPx1-deficient mice.
    Rasmiena AA; Barlow CK; Stefanovic N; Huynh K; Tan R; Sharma A; Tull D; de Haan JB; Meikle PJ
    Atherosclerosis; 2015 Dec; 243(2):598-608. PubMed ID: 26545014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice.
    Salim HM; Fukuda D; Higashikuni Y; Tanaka K; Hirata Y; Yagi S; Soeki T; Shimabukuro M; Sata M
    Vascul Pharmacol; 2017 Sep; 96-98():19-25. PubMed ID: 28347868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition.
    Wilck N; Fechner M; Dreger H; Hewing B; Arias A; Meiners S; Baumann G; Stangl V; Stangl K; Ludwig A
    Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1418-26. PubMed ID: 22516063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DBZ (Danshensu Bingpian Zhi), a Novel Natural Compound Derivative, Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice.
    Wang J; Xu P; Xie X; Li J; Zhang J; Wang J; Hong F; Li J; Zhang Y; Song Y; Zheng X; Zhai Y
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of mouse atherosclerosis by urokinase inhibition or with a limited-spectrum matrix metalloproteinase inhibitor.
    Hu JH; Touch P; Zhang J; Wei H; Liu S; Lund IK; Høyer-Hansen G; Dichek DA
    Cardiovasc Res; 2015 Mar; 105(3):372-82. PubMed ID: 25616415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.